How Effexor’s New GAD Approval And MR-139 Setback At Viatris (VTRS) Has Changed Its Investment Story
Viatris recently received approval in Japan for Effexor SR to treat generalized anxiety disorder (GAD), marking a positive development for expanding existing medicine indications. However, this progress is countered by the Phase 3 failure of MR-139 for blepharitis. These events are seen to modestly affect Viatris's investment narrative, particularly concerning its projected revenue and its ability to manage pricing pressures and pipeline risks.
Calix (NYSE:CALX) Upgraded at Wall Street Zen
Calix (NYSE:CALX) was upgraded from a "buy" to a "strong-buy" rating by Wall Street Zen, joining other bullish analyst actions. The company recently beat earnings expectations with $0.39 EPS and $272.4 million in revenue, leading to an average target price of $75.00 among analysts. Calix's board also authorized a $125 million share buyback program, with institutional investors owning a significant 98.14% of the company's stock.
Can Perrigo (PRGO) Cut Jobs Yet Sustain Innovation, Expansion and Its Dividend Commitment?
Perrigo Company plc announced plans to cut 7% of its global workforce, focus on core businesses, and deepen retailer partnerships to streamline operations amidst a soft market. This strategy aims to balance cost reductions with continued investment in innovation, geographic expansion, and maintaining its US$0.29 per share quarterly dividend, with 2027 targeted as a pivotal year for accelerating these plans. Investors are looking to see how these measures will impact profitability and address the risks posed by weak demand and intense competition, as the company projects $4.6 billion in revenue and $183.6 million in earnings by 2028.
Viatris Inc. stock falls Thursday, underperforms market
Viatris Inc. (VTRS) stock declined by 1.39% on Thursday, closing at $13.44. This fall occurred despite a mixed trading session for the broader market, with the S&P 500 Index rising and the Dow Jones Industrial Average falling. The stock's performance ended a two-day winning streak for Viatris.
Missile Strike Tests Teva Supply Resilience And Biosimilar Growth Plans
A recent missile strike in Israel, near a major Teva Pharmaceutical Industries manufacturing facility in Neot Hovav, has raised concerns about the company's operational continuity and supply chain resilience. While initial reports indicate limited direct damage, the incident highlights the geopolitical risks associated with concentrated pharmaceutical production, particularly as Teva expands into complex biologics. The event underscores the importance of robust backup capacity and contingency planning for investors monitoring Teva (NYSE:TEVA).
President of LENZ Therapeutics Evert Schimmelpennink Buys 57% More Shares
LENZ Therapeutics President Evert Schimmelpennink recently increased his stake in the company by 57%, purchasing US$251k worth of shares at US$8.95 each. This significant insider buying activity, along with other insider purchases over the last year, indicates optimism about the company's future, despite its recent losses. Insiders now own about 2.5% of the company's shares.
Pfizer stock hits 52-week high at 27.99 USD
Pfizer stock has reached a new 52-week high of $27.99, demonstrating a strong performance with a 1-year total return of 17.54% and a dividend yield of 6.19%. This surge is attributed to investor confidence, ongoing developments, and positive clinical trial results for its Lyme disease vaccine candidate and breast cancer drug. Additionally, the stock appears undervalued according to InvestingPro analysis, despite a recent mini-tender offer from Tutanota LLC at a potentially lower market value.
Biogen to buy Apellis Pharmaceuticals for $5.6 billion
Biogen has agreed to acquire Apellis Pharmaceuticals for approximately $5.6 billion in cash, aiming to expand its rare-disease drug portfolio. Apellis shareholders will receive $41 per share in cash, a significant premium, plus potential additional payments tied to the global sales of their eye disorder drug Syfovre. This announcement led to a substantial premarket rise in Apellis' share price.
Johnson & Johnson Stock Surged 60%, Here’s Why
Johnson & Johnson (JNJ) stock surged 60% between mid-2025 and early 2026 due to stronger-than-expected guidance, strategic portfolio changes including oncology pipeline additions, and a significant beat in Q4 2025 earnings. This growth reflects increased investor confidence despite challenges like the loss of exclusivity for Stelara and ongoing litigation. The article discusses the bull and bear cases, highlighting the tug-of-war between innovative pipeline growth and structural headwinds.
Is Effexor’s First-in-Class GAD Approval in Japan Altering The Investment Case For Viatris (VTRS)?
Viatris Inc. recently secured approval in Japan for Effexor SR capsules as the first treatment for generalized anxiety disorder (GAD), expanding its market beyond depression. This move aligns with Viatris's strategy to pivot towards higher-value, innovative medicines from commoditized generics, reinforcing its investment narrative for gradually improving earnings. While promising, this approval alone doesn't shift the immediate focus on cost savings and managing margin pressures in its core generics business.
VTRS PE Ratio & Valuation, Is VTRS Overvalued
Viatris Inc (VTRS) is currently considered undervalued, with its forward PE ratio of 5.22 being lower than its five-year average of 3.89. The company's fair price is estimated between $22.98 and $25.35, indicating it is undervalued by 43.21% compared to its current price of $13.05. Despite a robust revenue growth of 4.97%, its P/S ratio of 1.01 is significantly above the industry average, which the analysis suggests is unsustainable.
Organon & Co Stock: Steady Healthcare Player with Growth Potential Amid Market Pressures
Organon & Co, spun off from Merck, is a healthcare company focusing on women's health and biosimilars, offering North American investors a stable dividend payer with growth potential. The stock appears undervalued based on its price-to-earnings ratio and analyst projections, with key products like VTAMA and strategic initiatives aimed at expanding market reach. Despite market pressures and risks like patent expirations, the company's defensive portfolio and focus on accessible therapies position it for resilience and long-term value.
Viatris at $14: A Double-Digit FCF Yield Hiding in Plain Sight
Viatris (VTRS) is currently undervalued, trading at a significant discount despite strong free cash flow generation, aggressive share buybacks, and a promising pipeline. The company is set to launch a $650 million cost savings program in 2026 and expects multiple regulatory decisions this year, contributing to an anticipated inflection point. Investors are encouraged to consider the company's robust global distribution platform and debt reduction efforts, which position it for substantial upside.
Vanguard (VTRS) Amendment No.3: Reports 0% Beneficial Ownership After Realignment
The Vanguard Group filed Amendment No. 3 to a Schedule 13G/A, reporting 0% beneficial ownership of Viatris Inc. Common Stock (VTRS). This change is due to an internal realignment on January 12, 2026, which led to certain subsidiaries and business divisions disaggregating from The Vanguard Group and now reporting their beneficial ownership separately. The filing confirms that The Vanguard Group itself no longer holds nor is deemed to hold beneficial ownership over these securities.
Monopar (NASDAQ: MNPR) 10-K outlines ALXN1840 deal, pipeline and runway
Monopar's latest 10-K filing details its strategic focus on ALXN1840 for Wilson disease, in-licensed from Alexion, and its MNPR-101 radiopharmaceutical programs for advanced cancers. The company reported $140.4 million in cash, cash equivalents, and investments as of December 31, 2025, which it expects to fund operations through at least December 31, 2027. Monopar anticipates submitting the New Drug Application for ALXN1840 in mid-2026 and is advancing clinical trials for its MNPR-101-based imaging and therapeutic agents.
Viatris Inc. stock falls Friday, underperforms market
Viatris Inc. (VTRS) shares fell 2.39% to $13.05 on Friday, marking its second consecutive day of losses. The decline occurred during a broad market downturn, with the S&P 500 Index and Dow Jones Industrial Average also experiencing significant drops.
Is It Time To Reassess Collegium Pharmaceutical (COLL) After The Recent Share Price Pullback?
Collegium Pharmaceutical (COLL) has experienced a 26% share price decline over the last month despite positive long-term returns. A Discounted Cash Flow (DCF) analysis suggests the stock is 82.2% undervalued, with an estimated intrinsic value of $187.83 per share compared to its current $33.42. The company's P/E ratio of 16.88x is in line with its industry average and below its "Fair Ratio" of 23.15x, further indicating it may be undervalued.
Jazz Pharmaceuticals (Nasdaq:JAZZ) - Stock Analysis
Jazz Pharmaceuticals (JAZZ) is trading at a significant discount to its fair value, with analysts forecasting a 22.3% stock price increase and earnings growth of 33.81% per year. The company's future growth is driven by new product launches and strategic acquisitions in neuroscience, rare cancers, and cannabinoid therapies, despite facing risks from patent expirations and high debt levels. Recent news highlights include strong financial performance, ongoing R&D, key product approvals, and insider selling activities.
Empowering the Front Lines: How the NCD Academy Is Transforming Community Level Care
The NCD Academy, a free online education platform, is providing high-quality training to healthcare professionals worldwide to combat noncommunicable diseases (NCDs). This initiative, supported by Viatris, aims to empower general practitioners, nurses, pharmacists, and community health workers, especially in areas with limited medical access. The platform has already educated thousands across 165 countries, significantly contributing to global health by equipping front-line clinicians with essential knowledge and tools.
Viatris Inc officer Campbell sells $283k in shares By Investing.com
Viatris Inc.'s Chief Accounting Officer, Paul Campbell, sold 21,350 shares worth $283,538 on March 23, 2026. Despite the recent stock decline, Viatris is considered undervalued by InvestingPro analysis, with a fair value of $15.43 against a current price of $13.35. The company also recently announced ambitious financial targets, including significant revenue and EBITDA growth through 2030, and received approval for a new drug in Japan.
Viatris Named to 3BL’s 100 Best Corporate Citizens of 2023 Ranking
Viatris Inc. has been recognized on 3BL’s annual 100 Best Corporate Citizens ranking for its strong environmental, social, and governance (ESG) transparency and performance among the largest U.S. public companies. This recognition highlights the company's commitment to corporate social responsibility, building sustainable access to medicine, and advancing responsible operations. The ranking is based on 184 ESG factors across seven pillars and uses data collected from publicly available sources from the Russell 1,000 Index companies.
Viatris Inc. stock rises Wednesday, outperforms market
Viatris Inc. (VTRS) saw its stock increase by 1.05% to $13.50 on Wednesday, outperforming the broader market. Both the S&P 500 Index and the Dow Jones Industrial Average also rose during the session. This marks the third consecutive day of gains for Viatris's stock.
Anavex Life Sciences Corp Faces Competitive Pressure Amid Financial Year Results
Anavex Life Sciences Corp. (NASDAQ: AVXL) has seen its stock drop by over 30% following unimpressive clinical trial results and an operating loss of $6.78M due to high R&D expenses. Despite financial volatility and investor wariness, the company maintains a strong cash position of $131.75M and a zero-debt-to-equity ratio, indicating financial resilience. The market's reaction hinges on whether Anavex's ongoing research investments will translate into significant breakthroughs and future financial success.
Viatris Inc officer Campbell sells $283k in shares
Viatris Inc.'s Chief Accounting Officer, Paul Campbell, sold 21,350 shares of common stock for a total of $283,538. This transaction occurred amidst a recent decline in the stock's value, though it remains up significantly over the past six months. The company has also announced ambitious financial growth targets and regulatory approvals, leading to mixed but generally positive analyst outlooks.
Viatris (VTRS) insider trims stake with 21,350-share open-market sale
Viatris Inc. officer Paul Campbell reported an open-market sale of 21,350 shares of common stock at a weighted average price of $13.2805 per share. Following this transaction, Campbell still holds a substantial position with 366,288 shares directly and an additional 318 shares indirectly through a 401(k) plan. The SEC Form 4 filing details the transaction and confirms it as an open-market sale.
Is WisdomTree U.S. MidCap Dividend ETF (DON) a Strong ETF Right Now?
The article analyzes the WisdomTree U.S. MidCap Dividend ETF (DON), an ETF launched in 2006 focusing on mid-cap value dividend-paying companies. It details the fund's smart beta strategy, expense ratio of 0.38%, sector allocation, top holdings, and performance, including a 0.7% year-to-date return and 8.05% over the past year. The analysis concludes that DON is a reasonable option for investors but also suggests alternatives like IWS and VOE, particularly for those seeking lower costs.
Theravance Biopharma 2025 10-K: $107.5M Revenue, $105.9M Net Income
Theravance Biopharma reported total revenues of $107.5 million and net income of $105.9 million for 2025, significantly boosted by non-recurring items like the sale of contingent royalty assets and the TRELEGY sale. The company ended the year with strong operating cash generation and a substantial cash balance, benefiting from strategic realignments including winding down R&D and reducing operating expenses. Sales of YUPELRI also showed significant growth, contributing to improved brand profitability.
[144] Viatris Inc SEC Filing
Viatris Inc. has filed a Form 144 with the SEC, indicating a proposed sale of 21,350 shares of common stock with an aggregate market value of $283,508.28. The shares were acquired through the vesting of stock awards on March 3, 2026, and are intended to be sold on NASDAQ on March 23, 2026, through Merrill Lynch. The filing also includes a representation that the selling person is unaware of any material adverse information concerning Viatris Inc. that has not been publicly disclosed.
Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD)
Viatris announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Effexor® SR for the treatment of adults with generalized anxiety disorder (GAD), making it the first and only approved treatment option for GAD in Japan. This approval addresses a significant unmet medical need and builds on Effexor®'s existing approval for major depressive disorder in the country. The decision is based on a Phase 3 study showing the drug's superiority in anxiolytic effects and a generally well-tolerated safety profile.
Barclays raises Viatris stock price target on pipeline potential
Barclays has increased its price target for Viatris Inc. (NASDAQ:VTRS) to $17.00 from $15.00, maintaining an Overweight rating, citing the company's valuation and underappreciated revenue upside and pipeline. Despite a muted market reaction to Viatris' Investor Day, the firm sees ample near-term upside due to expected catalysts in fiscal year 2026. This positive outlook follows Viatris' strong Q4 2025 financial results and strategic approvals, though other analysts have mixed ratings and targets.
Barclays raises Viatris stock price target on pipeline potential
Barclays has increased its price target for Viatris Inc. to $17.00 from $15.00, maintaining an Overweight rating, citing the company's valuation and potential revenue upside from its pipeline. The firm expects a strong catalyst path in fiscal year 2026. This follows recent positive financial results, including exceeding analyst expectations for Q4 2025 earnings and revenue, and outlining ambitious financial targets through 2030, alongside other analyst upgrades and a new drug approval in Japan.
Viatris’ Effexor Approved in Japan for Generalized Anxiety Disorder
Viatris Inc. has received approval from Japan's Ministry of Health, Labour and Welfare for Effexor (venlafaxine hydrochloride) 37.5 mg / 75 mg capsules for the treatment of generalized anxiety disorder (GAD) in adults. This makes Effexor the first approved treatment option for GAD in Japan, building on its existing approval for major depressive disorder. The approval was based on a successful Phase 3 study demonstrating the anxiolytic effects of venlafaxine compared to placebo.
Pfizer says long-awaited Lyme vaccine was effective in study
Pfizer announced its experimental Lyme disease vaccine was 73% effective in a study, though lower-than-expected infection rates in participants made assessing its large-scale effectiveness challenging. Despite this, Pfizer is confident in the vaccine's potential and plans to seek regulatory approval. There is currently no human Lyme vaccine on the market, and cases of the tick-borne illness have surged significantly since the last vaccine was pulled in 2002.
Just – Evotec Biologics wins BARDA contract to optimise antibody biomanufacturing against Ebola and Sudan virus
Just – Evotec Biologics has been awarded a multi-year contract worth up to $10 million by BARDA's BioMaP Consortium. The contract focuses on optimizing the manufacturing of a monoclonal antibody cocktail for filovirus diseases, specifically targeting Ebola and Sudan viruses, to enhance national preparedness and response capabilities. The company will utilize its technology platforms for molecular optimization, cell line development, and manufacturing process development for two antibodies.
Viatris Says Japan Regulator Approves Effexor for Generalized Anxiety Disorder in Adults
Viatris Inc. announced that the Japan regulator has approved Effexor (venlafaxine hydrochloride) for the treatment of generalized anxiety disorder in adults. This approval expands the use of Effexor in the Japanese market. Viatris is a global healthcare company with operations across developed, Greater China, JANZ, and emerging markets.
Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD)
Viatris Inc. announced that Japan's Ministry of Health, Labour and Welfare has approved Effexor® SR capsules for treating generalized anxiety disorder (GAD) in adults. This makes Effexor® the first and only approved treatment for GAD in Japan, addressing a significant unmet medical need. The approval was based on a successful Phase 3 study showing the drug's effectiveness and safety profile.
Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD)
Viatris Inc. announced that Japan's Ministry of Health, Labour and Welfare has approved Effexor® SR for treating generalized anxiety disorder (GAD) in adults. This makes Effexor® the first and only approved treatment for GAD in Japan, addressing a significant unmet medical need. The approval is based on a successful Phase 3 study showing the drug's efficacy and tolerability.
Japan clears Effexor as first approved GAD treatment for adults
Viatris (Nasdaq: VTRS) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Effexor SR 37.5 mg / 75 mg capsules for adults with Generalized Anxiety Disorder (GAD). This approval makes Effexor the first and only GAD treatment in Japan, addressing a significant unmet medical need. The decision is supported by a successful Phase 3 study and long-term extension data, demonstrating anxiolytic effects and a consistent safety profile.
Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD)
Viatris Inc. announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Effexor® SR for the treatment of adults with generalized anxiety disorder (GAD). This makes Effexor® the first and only approved treatment option for GAD in Japan, addressing a significant unmet medical need. The approval is based on a Phase 3 study demonstrating the superiority of venlafaxine over placebo in reducing anxiety symptoms.
Collegium Pharmaceutical (COLL) Valuation Check After Recent Share Price Volatility
Collegium Pharmaceutical (COLL) has experienced stock price volatility, with recent declines offset by a stronger long-term return. Despite this, the company is considered undervalued by Simply Wall St, with a fair value of $53.83 compared to its current $35.44 trading price, mainly due to its differentiated pain portfolio and expected margin improvements. Investors are urged to consider potential risks like patent expirations and operating costs, alongside the company's P/E ratio, which is slightly above the industry average but below its peer average.
How (VTRS) Movements Inform Risk Allocation Models
This article analyzes Viatris Inc. (VTRS) movements, noting divergent sentiment across time horizons and suggesting choppy conditions. It presents AI-generated trading strategies for different risk profiles, including long, breakout, and short setups, and provides multi-timeframe signal analysis with support and resistance levels. The content also offers access to real-time signals and personalized dashboard features for subscribers.
If You Invested $1,000 in United Therapeutics Corp. (UTHR)
This article analyzes the historical performance of United Therapeutics Corp. (UTHR) stock, showing how a $1,000 investment would have grown over 1, 5, and 10 years, and includes a year-by-year return comparison against the S&P 500. It also provides a detailed overview of the company, its therapeutic focus in cardiopulmonary diseases and organ transplantation, its public benefit corporation status, and its commercial products and clinical pipeline. The article highlights UTHR's strong returns, outperforming the S&P 500 over the past decade, and details its market position and innovative projects in xenotransplantation.
What Investors Need to Understand About a $24 Million Sale in a Medical Device Stock That Has Fallen 9% Over the Past Year
Invenomic Capital Management has sold its entire $24 million stake in Haemonetics Corporation (NYSE:HAE), a medical device company specializing in blood and plasma management. This divestment follows a period of volatile performance for Haemonetics, which saw its stock fall 9% over the past year despite a surge after strong Q3 results, subsequently giving back 27% of those gains this year. While the company's revenue growth has become more complex due to divestitures and changing product mix, profitability has improved with rising gross margins and operating income.
What Investors Need to Understand About a $24 Million Sale in a Medical Device Stock That Has Fallen 9% Over the Past Year
Invenomic Capital Management has fully divested its $24.29 million stake in Haemonetics Corporation (NYSE:HAE), a medical device company specializing in blood and plasma management. This sale occurred after Haemonetics shares surged nearly 70% in the previous quarter but have since dropped 27% this year, contributing to a 9% decline over the past year. While Haemonetics is facing challenges like inconsistent performance and divestitures, its profitability is improving with rising gross margins and operating income.
Theravance's Q4 Earnings and Revenues Miss Estimates
Theravance Biopharma (TBPH) reported fourth-quarter 2025 adjusted earnings of 6 cents per share and total revenues of $45.9 million, both missing Zacks Consensus Estimates. The company also announced the discontinuation of its ampreloxetine program after its pivotal Phase III study failed to meet endpoints, leading to a strategic review, including a potential sale of the company, and a major organizational restructuring with a 50% workforce reduction. These actions are aimed at optimizing costs and focusing on its commercial product, Yupelri, expecting significant cost savings and annualized cash flow.
Collegium Pharmaceutical Expands ADHD Portfolio With AZSTARYS And Valuation Gap
Collegium Pharmaceutical (NasdaqGS:COLL) has acquired AZSTARYS, a move that significantly expands its ADHD portfolio and secures longer-term product exclusivity for its ADHD offerings. This transaction is expected to be immediately accretive to adjusted EBITDA. The acquisition positions Collegium to navigate competitive pressures in the branded drug market by adding a differentiated ADHD asset.
$11B cash by 2030 gives Viatris room for deals and shareholder returns
Viatris (VTRS) has unveiled a strategic plan targeting sustained revenue and earnings growth through 2030, projecting over $11 billion in cash for deployment. The plan includes a 5%-6% total revenues CAGR, 7%-8% adjusted EBITDA CAGR, and 9%-10% adjusted EPS CAGR, alongside more than $3 billion in free cash flow by 2030. The company also identified $650 million in gross cost savings, with half of the deployable cash allocated for accretive business development and the rest for shareholder returns.
Will Viatris’ 2030 Capital and R&D Framework Reset the Core Investment Narrative for VTRS?
Viatris Inc. recently outlined its long-term vision, growth priorities, R&D focus, and financial framework through 2030 at an Investor Event. The company plans to use anticipated product launches, a developing pipeline, business development, and cash flow to fund both reinvestment and shareholder returns, maintaining its 2026 dividend policy despite recent losses. This framework aims to reshape Viatris's investment narrative, moving past its generics-heavy portfolio toward sustainable cash generation by 2030, though execution on new launches and ongoing pricing pressures remain key challenges.
Viatris Inc. stock falls Thursday, underperforms market
Viatris Inc. (VTRS) stock declined by 1.75% on Thursday, closing at $13.50, underperforming the broader market. This drop occurred on a day when both the S&P 500 Index and the Dow Jones Industrial Average also fell, marking the stock's second consecutive day of losses.
Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030
Viatris Inc. will hold its Investor Event to detail its strategic vision and financial framework aimed at sustaining revenue and earnings growth through 2030. The company anticipates a re-evaluation of its portfolio towards higher-margin generics and new launches, expecting to generate over $11 billion in cash for deployment to shareholders and business development. Long-term targets include a 5-6% Total Revenues CAGR, 7-8% Adjusted EBITDA CAGR, and 9-10% Adjusted EPS CAGR, alongside annual free cash flow exceeding $3 billion by 2030.
